2023年12月最新中科院分区表数据已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Liver Cancer LIVER CANCER （此期刊被最新的JCR期刊SCIE收录） LetPub评分 8.5
51人评分
我要评分
声誉 9.9 影响力 7.7 速度 7.0 | |||||||||||||||||||||
| 期刊ISSN | 2235-1795 | 微信扫码收藏此期刊 | ||||||||||||||||||||
| E-ISSN | 1664-5553 | |||||||||||||||||||||
| 2022-2023最新影响因子 （数据来源于搜索引擎） | 13.8 点击查看影响因子趋势图 | |||||||||||||||||||||
| 实时影响因子 | 截止2024年3月26日：10 | |||||||||||||||||||||
| 2022-2023自引率 | 7.20%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年影响因子 | 12.5 | |||||||||||||||||||||
| h-index | 25 | |||||||||||||||||||||
| CiteScore |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | https://www.karger.com/Journal/Home/255487 | |||||||||||||||||||||
| 期刊投稿网址 | https://www.manuscriptmanager.net/sLib/v4/login.php?paramScreen=bcN+I3CS9qwx940f/BPvJ/MzoRzVWdbdT6ew8aLp8Yk= | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Liver Cancer的语言要求，还能让Liver Cancer编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Liver Cancer编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | ALLSCHWILERSTRASSE 10, BASEL, SWITZERLAND, CH-4009 | |||||||||||||||||||||
| 出版商 | S. Karger AG | |||||||||||||||||||||
| 涉及的研究方向 | Medicine-Oncology | |||||||||||||||||||||
| 出版国家或地区 | SWITZERLAND | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | ||||||||||||||||||||||
| 出版年份 | 0 | |||||||||||||||||||||
| 年文章数 | 52点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 99.33% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 80.77% | |||||||||||||||||||||
| WOS期刊SCI分区 （ 2022-2023年最新版） | WOS分区等级：1区
| |||||||||||||||||||||
| 中科院《国际期刊预警 名单（试行）》名单 | 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2023年12月最新升级版） | 点击查看中科院SCI期刊分区趋势图
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2022年12月升级版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2235-1795%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 16 Weeks | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Liver Cancer顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | First-line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis Author: Fong, Khi Yung; Zhao, Joseph Jonathan; Sultana, Rehena; Lee, Joycelyn Jie Xin; Lee, Suat Ying; Chan, Stephen Lam; Yau, Thomas; Tai, David Wai Meng; Sundar, Raghav; Too, Chow Wei Journal: LIVER CANCER. 2023; Vol. 12, Issue 1, pp. 7-18. DOI: 10.1159/000526639 PubMed DOI |
| 2. | Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated With Atezolizumab Plus Bevacizumab Author: Hsu, Chiun; Ducreux, Michel; Zhu, Andrew X.; Qin, Shukui; Ikeda, Masafumi; Kim, Tae-You; Galle, Peter R.; Finn, Richard S.; Chen, Ethan; Ma, Ning; Hu, Youyou; Li, Lindong; Cheng, Ann-Lii Journal: LIVER CANCER. 2023; Vol. 12, Issue 1, pp. 44-56. DOI: 10.1159/000525499 PubMed DOI |
| 3. | Dietary fat composition affects hepatic angiogenesis and lymphangiogenesis in HCV core gene transgenic mice Author: Diao, Pan; Wang, Yaping; Jia, Fangping; Wang, Xiaojing; Hu, Xiao; Kimura, Takefumi; Sato, Yoshiko; Moriya, Kyoji; Koike, Kazuhiko; Nakayama, Jun; Tanaka, Naoki Journal: LIVER CANCER. 2023; Vol. 12, Issue 1, pp. 57-71. DOI: 10.1159/000525546 PubMed DOI |
| 4. | Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial Author: Ren, Zhenggang; Ducreux, Michel; Abou-Alfa, Ghassan K.; Merle, Philippe; Fang, Weijia; Edeline, Julien; Li, Zhiwei; Wu, Lihua; Assenat, Eric; Hu, Sheng; Rimassa, Lorenza; Zhang, Tao; Blanc, Jean-Frederic; Pan, Hongming; Ross, Paul; Yen, Chia-Jui; Tran, Albert; Shao, Guoliang; Bouattour, Mohamed; Chen, Yajin; Meyer, Tim; Hou, Jinlin; Tougeron, David; Bai, Yuxian; Hou, Ming-Mo; Meng, Zhiqiang; Wu, John; Li, Vincent; Chica-Duque, Sandra; Cheng, Ann-Lii Journal: LIVER CANCER. 2023; Vol. 12, Issue 1, pp. 72-84. DOI: 10.1159/000527175 PubMed DOI |
| 5. | Combined hepatocellular-cholangiocarcinoma: biology, diagnosis, and management Author: Ye, Liangtao; Schneider, Julia S. S.; Ben Khaled, Najib; Schirmacher, Peter; Seifert, Carolin; Frey, Lea; He, Yulong; Geier, Andreas; De Toni, Enrico N. N.; Zhang, Changhua; Reiter, Florian P. P. Journal: LIVER CANCER. 2023; Vol. , Issue , pp. -. DOI: 10.1159/000530700 DOI |
| 6. | Predictive and prognostic potential of liver function assessment in patients with advanced hepatocellular carcinoma: a systematic literature review Author: Vogel, Arndt; Kelley, Robin Katie; Johnson, Philip; Merle, Philippe; Yau, Thomas; Kudo, Masatoshi; Meyer, Tim; Rimassa, Lorenza Journal: LIVER CANCER. 2023; Vol. , Issue , pp. -. DOI: 10.1159/000529173 DOI |
| 7. | Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Hepatocellular Carcinoma <= 5 cm: Biological Characteristics and Patient Outcomes Author: Cai, Wen-Jia; Ying, Minghua; Zheng, Rong-Qin; Liao, Jintang; Luo, Baoming; Tang, Lina; Cheng, Wen; Yang, Hong; Wei, An; Yang, Yilin; Wang, Hui; Luo, Yan-Chun; Liu, Cun; Zhong, Hui; Yang, Qi; Yu, Jie; Liang, Ping Journal: LIVER CANCER. 2023; Vol. , Issue , pp. -. DOI: 10.1159/000527498 DOI |
| 8. | Achievement of Complete Response and Drug-free Status by Atezolizumab Plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-stage Hepatocellular Carcinoma: A Multicenter Proof-of-Concept Study Author: Kudo, Masatoshi; Aoki, Tomoko; Ueshima, Kazuomi; Tsuchiya, Kaoru; Morita, Masahiro; Chishina, Hirokazu; Takita, Masahiro; Hagiwara, Satoru; Minami, Yasunori; Ida, Hiroshi; Nishida, Naoshi; Ogawa, Chikara; Tomonari, Tetsu; Nakamura, Noriaki; Kuroda, Hidekatsu; Takebe, Atsushi; Takeyama, Yoshifumi; Hidaka, Masaaki; Eguchi, Susumu; Chan, Stephen L.; Kurosaki, Masayuki; Izumi, Namiki Journal: LIVER CANCER. 2023; Vol. , Issue , pp. -. DOI: 10.1159/000529574 DOI |
| 9. | Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial Author: Merle, Philippe; Kudo, Masatoshi; Edeline, Julien; Bouattour, Mohamed; Cheng, Ann-Lii; Chan, Stephen Lam; Yau, Thomas; Garrido, Marcelo; Knox, Jennifer; Daniele, Bruno; Breder, Valeriy; Lim, Ho Yeong; Ogasawara, Sadahisa; Cattan, Stephane; Chao, Yee; Siegel, Abby B.; Martinez-Forero, Ivan; Wei, Ziwen; Liu, Chih-Chin; Finn, Richard S. Journal: LIVER CANCER. 2023; Vol. , Issue , pp. -. DOI: 10.1159/000529636 DOI |
| 10. | Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study Author: Kudo, Masatoshi; Finn, Richard S.; Cheng, Ann-Lii; Zhu, Andrew X.; Ducreux, Michel; Galle, Peter R.; Sakamoto, Naoya; Kato, Naoya; Nakano, Michitaka; Jia, Jing; Vogel, Arndt Journal: LIVER CANCER. 2023; Vol. , Issue , pp. -. DOI: 10.1159/000529996 DOI |
|
|
  | |
|
以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分： | |
同领域作者分享投稿经验：共0条 （包含回复） |
我来分享 |
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2024 中国: LetPub上海分公司 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960
增值电信业务经营许可证：沪B2-20211595
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451
安全保密
